Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Cytotherapy. 2021 Apr 5;23(8):694–703. doi: 10.1016/j.jcyt.2021.03.001

Figure 2.

Figure 2.

Off-the-Shelf TAA-T cells are cytolytic against Wilms Tumor cell lines

(A) Wilms tumor cell lines 17.94 (left) and Wit49 (middle) stained positive for PRAME by immunofluorescence, compared to pancreatic cells, negative control (right). (B) TAA-T products are polyclonal and demonstrate cytokine secretion upon stimulation with PRAME as measured by flow cytometry and intracellular cytokine staining. (C) TAA-T products demonstrate specificity for PRAME as measured by IFN-γ ELISpot assay (background response to actin subtracted from final results). (D)-(I) PRAME specific TAA-T products demonstrate antigen-specific cytotoxicity to Wilms tumor cell lines 17.94 (D)(F)(G) and Wit49 (F)(H) with absent non-specific activity to autologous PHA blasts or PBMCs (I).